Ventana Developing CDx for Seattle Genetics, Millenium Cancer Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ventana is developing a companion diagnostic test for an oncology drug developed by Seattle Genetics and Millennium Pharmaceuticals under a deal announced today.

The companion diagnostic being developed by Ventana, a Roche company, will be for identifying patients who best respond to Adcetris (brentuximab vedotin) based on CD30 expression levels in their tissue specimens. Under the terms of the agreement, Ventana will develop, manufacture, and commercialize the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.